Skip to content

Clinical study on the safety and efficacy of autologous bone marrow mesenchymal stem cells and their related derivatives in the treatment of limbal stem cell deficiency

Clinical study on the safety and efficacy of autologous bone marrow mesenchymal stem cells and their related derivatives in the treatment of limbal stem cell deficiency

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059018
Enrollment
Unknown
Registered
2022-04-23
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal burns

Interventions

Experimental group:Transplantation of autologous bone marrow mesenchymal stem cells and their derivatives

Sponsors

The First Affiliated Hospital of Army Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Sign informed consent voluntarily as the subject. 2. Aged between 18 and 70 years, regardless of gender. 3. Make a clear diagnosis of moderate to severe ocular surface thermal burn and chemical burn. 4. Corrected vision: BCVA<=0.1. 5. Moderate to severe eye surface burns.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating patients. 2. Patients who have undergone corneal transplantation. 3. Incomplete eyelid closure caused by eyelid injury affects the recovery of ocular surface. 4. The recovery of ocular surface is affected by eyelid insufficiency caused by ocular protrusion. 5. Moderate to severe primary diseases of cardiovascular, liver, kidney and hematopoietic system. 6. Combined with mental illness and mental illness. 7. Previous human immunodeficiency virus and other infections. 8. Patients with systemic or topical application of other drugs affecting the evaluation of efficacy. 9. Participated in other clinical trials in the past three months.

Design outcomes

Primary

MeasureTime frame
Clinical symptoms and eye signs before and after treatment;Evaluation of visual function improvement;

Countries

China

Contacts

Public ContactLiu Yong

The First Affiliated Hospital of Army Military Medical University

liuyy99@163.com+86 13983732105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026